RecruitingNot ApplicableNCT06684028
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
Sponsor
Affiliated Hospital of Jiangnan University
Enrollment
30 participants
Start Date
Jul 12, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria4
- The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
- Age 18-85 years old, male or female;
- Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
- ECOG score is 0-3 points;
Exclusion Criteria4
- Patients with a history or allergic constitution to any component of the developer, including alcohol;
- pregnant or lactating women;
- Patients with mental illness or related history;
- Patients who cannot or cannot undergo a PET/CT scan;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG68Ga-FAPI-JNU
Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06684028
Related Trials
Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study
NCT069527901 location
Daily Hand-Held Vibration Therapy
NCT042074373 locations
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT0591926433 locations
Pan Tumor Rollover Study
NCT03899155399 locations
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT075384791 location